Well the difference for some is that selling at .13 is will net a nice chunk of profit. If this does reverse split and it the share price plummets like the last time they r/s in 2019 then all the gains for people who got in cheap are wiped out. For those of you in at .10 to .12 it may be worth it to ride or die on this. Other people are up a significant amount and it's a question of pushing the chips all in or reading the players and getting the most out of the investment.
I'm not saying retail investors will be fleeced, I'm asking if anyone else has some insight as to that fine print in the S-1. Like I said I'm no lawyer, but i can read. It sounds a little off and this is the OTC and it was back in February when they started the mice trials and we haven't heard sh*t about them in 8 months. I remember people saying 2 weeks after that we would get results soon.
News 
Market Data 
Discover 
AI
